Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial
Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.
Authors
- Yuyi Wang (ORCID: https://orcid.org/0000-0002-4031-0420)
- Min Li (ORCID: https://orcid.org/0000-0003-4853-4258)
- Chuangang Ning (ORCID: https://orcid.org/0000-0002-3158-1253)
- Qingchun Diao
- Yan Huang (ORCID: https://orcid.org/0000-0001-7607-9585)
- Qin Zhang (ORCID: https://orcid.org/0000-0002-7083-8947)
- Jiajia Li (ORCID: https://orcid.org/0000-0002-4932-7931)
- Peng Zhao (ORCID: https://orcid.org/0000-0003-2034-6810)
- Fang Lu
- Ruiling Jia
- Juan Long (ORCID: https://orcid.org/0009-0003-8567-2331)
Institutions
- Integrative Medicine Institute (US)
- Chongqing Emergency Medical Center (CN)
- First People's Hospital of Chongqing (CN)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1080/09546634.2025.2591478
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00